Kausik K. Ray (United Kingdom)

Imperial College London Department of Primary Care and Public Health
Kausik Ray is currently Professor of Public Health, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London, Consultant Cardiologist and Chief Clinical Officer and Head of Trials –Discover Now as well as NIHR ARC National Lead of Cardiovascular Disease. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a post-doctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and President of the European Atherosclerosis Society, also serving on the EAS Consensus panel and EAS Executive Committee. Professor Ray has either been the National Lead Investigator, Principal Investigator, or served on committees for several major medical trials, as well as international registries and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1, 3, 11 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 87, an i10 of 220 and over 92,000 citations for his work in journals such as New England Journal of Medicine, The Lancet, JAMA, European Heart Journal, Circulation and JACC. He has also been included in the Clarivate Analytics’ list of the top 1% most cited authors in all of global medicine in 2018, 2019 and 2020. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH which includes 70 countries and 62,000 cases, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Author Of 24 Presentations

Panel discussion (ID 1559)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
10:20 - 10:29

Introduction (ID 1518)

Session Type
Joint Session
Session Time
16:00 - 17:45
Date
Mon, 31.05.2021
Room
Hall G
Lecture Time
16:00 - 16:03

Live Q&A (ID 1386)

Session Type
CME Session
Session Time
12:45 - 14:00
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
13:33 - 14:00

Treating to Risk- Beyond LDL-C in decision making for LDL-C lowering (ID 1538)

Session Type
Industry Sponsored Session
Session Time
18:00 - 19:30
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
18:45 - 19:05

Case study related to ‘Are the ESC/EAS LLT pathways fit for everyday practice – new insights from the DA VINCI and HEYMANS studies’ (ID 1564)

Session Type
Industry Sponsored Session
Session Time
12:30 - 13:15
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
12:33 - 12:43

Conclusion (ID 1520)

Session Type
Joint Session
Session Time
16:00 - 17:45
Date
Mon, 31.05.2021
Room
Hall G
Lecture Time
17:38 - 17:41

Prevention at a population level-putting theory into practice (ID 1389)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:04 - 15:19

Two cases of discussion regarding typical but difficult to treat patients at varying levels of CV risk (ID 1539)

Session Type
Industry Sponsored Session
Session Time
18:00 - 19:30
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
19:05 - 19:20

Welcome by EAS president (ID 1591)

Session Type
Plenary Session
Session Time
09:00 - 09:30
Date
Mon, 31.05.2021
Room
Live Streamed
Lecture Time
09:02 - 09:10

Introduction (ID 1526)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Mon, 31.05.2021
Room
Hall A (Live Q&A)
Lecture Time
14:30 - 14:33

Live Q&A (ID 1390)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:20 - 15:45

Introduction (ID 1497)

Session Type
Joint Session
Session Time
15:30 - 17:00
Date
Tue, 01.06.2021
Room
Hall C
Lecture Time
15:30 - 15:33

Young Investigator Awardees (ID 1601)

Session Type
Plenary Session
Session Time
13:30 - 14:25
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
14:13 - 14:18

Overcoming barriers to population health-through siRNA based therapies (ID 1530)

Session Type
Meet the experts
Session Time
16:30 - 17:00
Date
Mon, 31.05.2021
Room
Meet the expert session hall
Lecture Time
16:30 - 17:00

Are the ESC/EAS LLT pathways fit for everyday practice – new insights from the DA VINCI and HEYMANS studies (ID 1555)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
09:48 - 09:56

Introduction (ID 1515)

Session Type
Plenary Session
Session Time
13:30 - 14:25
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
13:30 - 13:33

Live Q&A (ID 1382)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Mon, 31.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:18 - 15:45

Introduction (ID 1622)

Session Type
Joint Session
Session Time
17:30 - 19:00
Date
Tue, 01.06.2021
Room
Hall A (Live Q&A)
Lecture Time
17:30 - 17:33

Opening remarks - Objectives of Symposium (ID 1535)

Session Type
Industry Sponsored Session
Session Time
18:00 - 19:30
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
18:00 - 18:05

O060 - Evolocumab use and LDL-C lowering in a cohort of European patients with familial hypercholesterolemia (FH) - results from the HEYMANS study (ID 1422)

Session Type
Late Breaking Sessions
Session Time
10:00 - 11:15
Date
Wed, 02.06.2021
Room
Hall A (Live Q&A)
Lecture Time
10:14 - 10:21

Abstract

Background and Aims

Describe real-world evolocumab use in FH patients.

Methods

This prospective observational cohort study enrolled adults ≥18 years old initiating evolocumab across 12 European countries from August 2015. The objectives were to describe clinical characteristics and LDL-C control among patients initiating evolocumab. We report data from patients with FH and follow up until July 2020.

Results

Of 1952 patients enrolled in HEYMANS, 766 (39%) had heterozygous (He) and 35 (1.8%) had homozygous (Ho) FH. Main diagnostic methods: Dutch lipid clinic network (40%), genetic testing (32%), LDL-C (19%). Mean age of FH patients, 57.2 (95% CI, 56.4-57.9) years; 56% male. Three-quarters (74%) of FH patients had additional comorbidities: hypertension, 55%; diabetes, 14%; chronic kidney disease stage ≥2, 5%; current/former smoker, 46%; body mass index ≥ 30, 22%. At evolocumab initiation, 45% of patients in the HeFH group were not receiving statins, 43% not receiving ezetimibe, 34% receiving high intensity statin+ezetimibe. Median (IQR) LDL-C in the HeFH group was 4.30 (3.39, 5.51) mmol/L at evolocumab initiation and dropped by 57% within 3 months; this reduction was maintained for up to 24 months (Figure 1). 55% of HeFH patients achieved an LDL-C <1.4 mmol/L following evolocumab initiation.

eas_figure.jpg

Conclusions

In this large study of European clinical practice, a large proportion of HeFH patients initiating evolocumab were not receiving statins and had LDL-C above 4 mmol/L, despite meeting the ESC/EAS definition of very high CV risk. Following evolocumab initiation, median LDL-C fell by over half and this reduction maintained for up to 24 months.

Hide

O064 - Are risk-based LDL-C goals achieved in primary and secondary care in Central and Eastern Europe? Comparison with other Europe regions from the DA VINCI observational study (ID 1412)

Session Type
Late Breaking Sessions
Session Time
10:00 - 11:15
Date
Wed, 02.06.2021
Room
Hall A (Live Q&A)
Lecture Time
10:42 - 10:49

Abstract

Background and Aims

Assess the proportion of patients in the Central and Eastern Europe (CEE) region achieving the risk-based LDL-C goals recommended by the 2016 and 2019 ESC/EAS guidelines. Compare with other Europe regions.

Methods

Data were collected at a single visit for adults who consented to participate, with any LLT in the past 12 months and an LDL-C measurement in the past 14 months. Primary outcome was LDL-C goal attainment ≥ 28 days after starting the most recent lipid lowering therapy (stabilized LLT).

Results

Out of 5888 total subjects, 2154 were enrolled from six CEE countries: Czech Republic, n=509; Hungary, n=319; Poland, n=460; Romania, n=259; Slovakia, n=123; Ukraine, n=484. Mean (SD) age, 64 (11) years; 48% female. Of 1476 subjects on stabilized LLT at LDL-C measurement, 664 (45%) were primary prevention and 812 (55%) secondary prevention. 53% were receiving moderate intensity statin monotherapy; 32% receiving high intensity statin monotherapy and 5% receiving ezetimibe combination therapy. Mean (SD) LDL-C was 97 mg/dL (2.5 mmol/L). 44% and 24% of patients achieved their risk-based LDL-C 2016 and 2019 goals, respectively. Goal attainment in the CEE region was lower than observed in Northern and Western Europe (Figure 1).

figure 1 - risk based ldl-c goal attainment.jpg

Conclusions

These data highlight a significant gap between guidelines and clinical practice for lipid management in the CEE region, with fewer than one-quarter of patients having LDL-C levels below the 2019 risk-based LDL-C goal. Risk-based goal attainment was lower than observed in Northern or Western Europe; combination therapy with non-statin LLT is needed to address this gap.

Hide

Presenter Of 23 Presentations

Overcoming barriers to population health-through siRNA based therapies (ID 1530)

Session Type
Meet the experts
Session Time
16:30 - 17:00
Date
Mon, 31.05.2021
Room
Meet the expert session hall
Lecture Time
16:30 - 17:00

Live Q&A (ID 1390)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:20 - 15:45

Are the ESC/EAS LLT pathways fit for everyday practice – new insights from the DA VINCI and HEYMANS studies (ID 1555)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
09:48 - 09:56

Introduction (ID 1515)

Session Type
Plenary Session
Session Time
13:30 - 14:25
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
13:30 - 13:33

Introduction (ID 1622)

Session Type
Joint Session
Session Time
17:30 - 19:00
Date
Tue, 01.06.2021
Room
Hall A (Live Q&A)
Lecture Time
17:30 - 17:33

Opening remarks - Objectives of Symposium (ID 1535)

Session Type
Industry Sponsored Session
Session Time
18:00 - 19:30
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
18:00 - 18:05

Panel discussion (ID 1559)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
10:20 - 10:29

Introduction (ID 1518)

Session Type
Joint Session
Session Time
16:00 - 17:45
Date
Mon, 31.05.2021
Room
Hall G
Lecture Time
16:00 - 16:03

Live Q&A (ID 1382)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Mon, 31.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:18 - 15:45

Treating to Risk- Beyond LDL-C in decision making for LDL-C lowering (ID 1538)

Session Type
Industry Sponsored Session
Session Time
18:00 - 19:30
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
18:45 - 19:05

Case study related to ‘Are the ESC/EAS LLT pathways fit for everyday practice – new insights from the DA VINCI and HEYMANS studies’ (ID 1564)

Session Type
Industry Sponsored Session
Session Time
12:30 - 13:15
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
12:33 - 12:43

Conclusion (ID 1520)

Session Type
Joint Session
Session Time
16:00 - 17:45
Date
Mon, 31.05.2021
Room
Hall G
Lecture Time
17:38 - 17:41

Live Q&A (ID 1386)

Session Type
CME Session
Session Time
12:45 - 14:00
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
13:33 - 14:00

Two cases of discussion regarding typical but difficult to treat patients at varying levels of CV risk (ID 1539)

Session Type
Industry Sponsored Session
Session Time
18:00 - 19:30
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
19:05 - 19:20

Welcome by EAS president (ID 1591)

Session Type
Plenary Session
Session Time
09:00 - 09:30
Date
Mon, 31.05.2021
Room
Live Streamed
Lecture Time
09:02 - 09:10

Introduction (ID 1526)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Mon, 31.05.2021
Room
Hall A (Live Q&A)
Lecture Time
14:30 - 14:33

Prevention at a population level-putting theory into practice (ID 1389)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:04 - 15:19

Introduction (ID 1497)

Session Type
Joint Session
Session Time
15:30 - 17:00
Date
Tue, 01.06.2021
Room
Hall C
Lecture Time
15:30 - 15:33

Young Investigator Awardees (ID 1601)

Session Type
Plenary Session
Session Time
13:30 - 14:25
Date
Mon, 31.05.2021
Room
Hall C
Lecture Time
14:13 - 14:18

O060 - Evolocumab use and LDL-C lowering in a cohort of European patients with familial hypercholesterolemia (FH) - results from the HEYMANS study (ID 1422)

Session Type
Late Breaking Sessions
Session Time
10:00 - 11:15
Date
Wed, 02.06.2021
Room
Hall A (Live Q&A)
Lecture Time
10:14 - 10:21

Abstract

Background and Aims

Describe real-world evolocumab use in FH patients.

Methods

This prospective observational cohort study enrolled adults ≥18 years old initiating evolocumab across 12 European countries from August 2015. The objectives were to describe clinical characteristics and LDL-C control among patients initiating evolocumab. We report data from patients with FH and follow up until July 2020.

Results

Of 1952 patients enrolled in HEYMANS, 766 (39%) had heterozygous (He) and 35 (1.8%) had homozygous (Ho) FH. Main diagnostic methods: Dutch lipid clinic network (40%), genetic testing (32%), LDL-C (19%). Mean age of FH patients, 57.2 (95% CI, 56.4-57.9) years; 56% male. Three-quarters (74%) of FH patients had additional comorbidities: hypertension, 55%; diabetes, 14%; chronic kidney disease stage ≥2, 5%; current/former smoker, 46%; body mass index ≥ 30, 22%. At evolocumab initiation, 45% of patients in the HeFH group were not receiving statins, 43% not receiving ezetimibe, 34% receiving high intensity statin+ezetimibe. Median (IQR) LDL-C in the HeFH group was 4.30 (3.39, 5.51) mmol/L at evolocumab initiation and dropped by 57% within 3 months; this reduction was maintained for up to 24 months (Figure 1). 55% of HeFH patients achieved an LDL-C <1.4 mmol/L following evolocumab initiation.

eas_figure.jpg

Conclusions

In this large study of European clinical practice, a large proportion of HeFH patients initiating evolocumab were not receiving statins and had LDL-C above 4 mmol/L, despite meeting the ESC/EAS definition of very high CV risk. Following evolocumab initiation, median LDL-C fell by over half and this reduction maintained for up to 24 months.

Hide

Moderator Of 8 Sessions

Date
Sun, 30.05.2021
Session Time
12:45 - 14:00
Room
Hall A (Live Q&A)
Date
Mon, 31.05.2021
Session Time
13:30 - 14:25
Room
Hall C

Meet the experts - Novel pathways for intensive lipid lowering (ID 56)

Date
Tue, 01.06.2021
Session Time
16:30 - 17:00
Room
Meet the expert session hall
Date
Mon, 31.05.2021
Session Time
18:00 - 19:30
Room
Industry session hall